<DOC>
	<DOCNO>NCT00495469</DOCNO>
	<brief_summary>This dose-ranging study evaluate efficacy , safety tolerability range dose GSK189075 ( SGLT2 inhibitor ) compare placebo , administer 12 week treatment-naive subject type 2 diabetes mellitus</brief_summary>
	<brief_title>Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects document diagnosis T2DM HbA1c ≥7.0 % ≤9.5 % measured central laboratory Visit 1 . Note : Subjects HbA1c &lt; 7.5 % must fast fingerstick glucose ≥7 mmol/L ( 126 mg/dL ) Week 0 , prior randomization . Note : The proportion subject randomize HbA1c &lt; 7.5 % limited 20 % ( approximately 51 subject ) Subjects treatmentnaïve , take insulin , oral injectable antidiabetic medication past 3 month take glucose lower agent ≥4 week time past , subject newly diagnose treat diet exercise minimum 6 week Subjects 18 70 year age inclusive time Screening . Females childbearing nonchildbearing potential eligible participate follow : Women childbearing potential must willing use one follow contraception method : intrauterine device , condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent least 30 day prior start study medication , throughout study followup visit . Note : use oral contraceptive permit . Women nonchild bear potential defined follow : female regardless age , function ovary current document tubal ligation , surgically sterile ( i.e . document total hysterectomy bilateral oophorectomy ) , females postmenopausal . All female must negative urine pregnancy test day , prior randomization . Informed Consent : sign date write consent must obtain subject procedure perform . Metabolic Disease Diagnosis Type 1 diabetes mellitus History ketoacidosis require hospitalization Thyroid disorder TSH &lt; 0.4 MIU/L ( &lt; 0.4 MCIU/mL ) &gt; 5.5 mIU/L ( &gt; 5.5 MCIU/mL ) Screening BMI &lt; 22 kg/m2 &gt; 43 kg/m2 Significant weight gain loss ( define &gt; 5 % total body weight ) 3 month prior Screening Diabetic Medication Has take insulin , oral injectable antidiabetic medication within 3 month screen Has take insulin oral injectable antidiabetic medication ≥4 week time past Cardiovascular Disease Recent history presence clinically significant acute cardiovascular disease include : Documented myocardial infarction 6 month prior Screening . Coronary revascularization include percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) surgery either plan and/or occur 6 month prior Screening . Unstable angina 6 month prior Screening . Clinically significant supraventricular arrhythmia require medical therapy , history nonsustained sustained ventricular tachycardia . Symptomatic valvular heart disease valvular heart disease require therapy endocarditis prophylaxis . Congestive heart failure ( CHF , New York Heart Association ( NYHA ) Class II IV ) require pharmacologic treatment NYHA Class criterion accordance local prescribe information pioglitazone . Blood pressure ( BP ) &gt; 150/100mmHg . If subject receiving permit antihypertensive therapy , must stable dose ( ) therapy least 4 week prior Screening . Based local reading , subject initial QTc interval ( Bazett 's ) ≥450msec Screening , two additional ECGs take 5 minute apart , average QTC interval three ECGs ≥450msec . Other clinically significant ECG abnormality , opinion Investigator , may affect interpretation efficacy safety data , otherwise contraindicate participation clinical trial new chemical entity . Fasting triglyceride ≥400mg/dL ( 4.56mmol/L ) Screening . If subject receiving permit lipidlowering therapy , must stable dose ( ) therapy least 6 week prior Screening . Niacin bile acid sequestrants prohibit . Hepatic Disease Has diagnosis active hepatitis ( hepatitis B surface antigen hepatitis C antibody ) , clinically significant hepatic enzyme elevation include : Any one following enzymes great 2 time upper limit reference range ( ULRR ) value Screening . alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) alkaline phosphatase ( AP ) Has total bilirubin level &gt; 1.5 time ULRR Screening exception suspect confirm Gilbert 's disease . Pancreatic Disease Secondary cause diabetes : history chronic acute pancreatitis Renal Disease Significant renal disease Screening manifest : Glomerular filtration rate ( GFR ) &lt; 60mL/min ( calculate Quest Visit use Modification Diet Renal Disease ( MDRD ) equation •≥1+ protein urine dipstick Trace ≥1+ leukocyte esterase urine dipstick Trace ≥1+ blood urine dipstick Positive nitrite urine dipstick Recurrent genitourinary tract infection define ≥2 episode complicate uncomplicated cystitis pyelonephritis 6 month prior Screening . Concurrent Disease Has concurrent condition clinically significant abnormality identify screen physical examination , laboratory test ( include blood electrolyte ) , ECG , include pulmonary , neurological inflammatory disease , , opinion investigator , may affect interpretation efficacy safety data , otherwise contraindicate participation clinical trial new chemical entity . History significant comorbid disease active 6 month prior Screening ( e.g. , cholecystitis , acute pancreatitis , gastrointestinal disease , chronic diarrhea , etc. ) . History malignancy within past 5 year superficial squamous cell carcinoma ( noninvasive pathology ) basal cell carcinoma ( successfully treat local excision ) . History cervical cancer situ treat definitively least 6 month prior Screening . Concurrent Medication Is currently take take follow medication 8 week prior Screening : Digoxin Warfarin oral anticoagulant ( aspirin nonsteroidal antiinflammatory drug permit ) Bile acid sequestrants Niacin ( exclude routine vitamin supplementation ) Antiobesity agent ( include fat absorption block agent ) Oral injectable corticosteroid ( inhale , topical intranasal corticosteroid permit ) Loop diuretic Monoamine oxidase inhibitor tricyclic amine Antiretroviral drug St John 's Wort Oral chromium 9.Breast Feeding 10.Other Current smoker unable abstain smoking clinic visit Has history alcohol substance abuse within past year Screening alcohol substance abuse treatment , determine investigator : Unwilling refrain use illicit drug adhere protocolstated restriction participate study Has average weekly intake alcohol &gt; 21 unit average daily intake &gt; 3 unit ( male ) average weekly intake &gt; 14 unit average daily intake &gt; 2 unit ( female ) . One unit equivalent half pint beer 1 measure spirit 1 glass wine Has participate study investigational market drug 3 month prior Screening . In opinion investigator risk noncompliance study procedure , read , understand , complete study related material , particularly inform consent . Known allergy tablet capsule excipients , history drug allergy , , opinion responsible study physician , contraindicate participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes mellitus HbA1c</keyword>
</DOC>